OP0151 A Phase 2B, 24-Week Study of VX-509 (DECERNOTINIB), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis

Abstract

BackgroundVX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). This was a 24-week, randomized, placebo-controlled, double-blind, phase 2 study of four dosing regimens...